# Sagimet Biosciences (SGMT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SGMT
## Company Profile
- Ticker: SGMT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic
## Stock Data
- Close: 9.39 USD
- Market cap: 419294769.53000003 USD
- Last updated: 2026-08-12
## Business Overview
### Metabolic Pathway Therapeutics
Sagimet Biosciences develops fatty acid synthase inhibitors for diseases driven by abnormal lipid production.
### Denifanstat
Denifanstat is an oral FASN inhibitor that reduces de novo lipogenesis and has been studied in both metabolic liver disease and dermatology.
### Dermatology Focus
Sagimet is prioritizing moderate-to-severe acne, where reduced sebaceous lipid synthesis may address an upstream disease mechanism.
## Why The Stock Is Moving

The latest monitored company update is “Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- A U.S. Phase 3 study of denifanstat in moderate-to-severe acne is planned to begin in the second half of 2026.

## Recent News
- 2026-08-13 11:00 EST — [Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-receives-fda-study-may-proceed-letter-and-ind-clearance-for--0441dcad) — Source: Sagimet Biosciences
- 2026-08-11 11:30 EST — [Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-reports-second-quarter-2026-financial-results-and-provides-c-17b8cabc) — Source: Sagimet Biosciences
- 2026-08-04 11:00 EST — [Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-to-participate-in-the-canaccord-genuity-46th-annual-growth-c-d57562ef) — Source: Sagimet Biosciences
- 2026-06-29 11:00 EST — [Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-joins-the-russell-2000-and-russell-3000-indexes-d9416ec4) — Source: Sagimet Biosciences
- 2026-06-23 00:49 EST — [Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-participation-in-upcoming-investor-conference-and--e1573657) — Source: Sagimet Biosciences